233 related articles for article (PubMed ID: 9723634)
41. Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).
Pitt B; Chang P; Grossman W; Dunlay M; Timmermans PB
Am J Cardiol; 1996 Nov; 78(10):1129-31. PubMed ID: 8914876
[TBL] [Abstract][Full Text] [Related]
42. The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.
Kvan E; Reikvam A;
Eur J Clin Pharmacol; 2004 May; 60(3):205-10. PubMed ID: 15034703
[TBL] [Abstract][Full Text] [Related]
43. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors.
Valdemarsson S; Edvinsson L; Ekman R; Hedner P; Sjöholm A
J Intern Med; 1991 Oct; 230(4):325-31. PubMed ID: 1717629
[TBL] [Abstract][Full Text] [Related]
44. Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure.
Feuring M; Jester I; Tillmann HC; Bertsch T; Kugler I; Schmidt BM; Wehling M
Methods Find Exp Clin Pharmacol; 2001 Sep; 23(7):409-13. PubMed ID: 11771856
[TBL] [Abstract][Full Text] [Related]
45. [Pharmacologic treatment of chronic congestive heart failure].
Halawa B
Przegl Lek; 1996; 53(3):119-23. PubMed ID: 8754362
[TBL] [Abstract][Full Text] [Related]
46. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group.
Gambassi G; Forman DE; Lapane KL; Mor V; Sgadari A; Lipsitz LA; Bernabei R
Am Heart J; 2000 Jan; 139(1 Pt 1):85-93. PubMed ID: 10618567
[TBL] [Abstract][Full Text] [Related]
47. A four-part regimen for clinical heart failure.
Freudenberger RS; Gottlieb SS; Robinson SW; Fisher ML
Hosp Pract (1995); 1999 Sep; 34(9):51-6, 59-64. PubMed ID: 10901760
[TBL] [Abstract][Full Text] [Related]
48. Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure.
Forman DE; Chander RB; Lapane KL; Shah P; Stoukides J
J Am Geriatr Soc; 1998 Dec; 46(12):1550-4. PubMed ID: 9848817
[TBL] [Abstract][Full Text] [Related]
49. The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice.
Missouris CG; MacGregor GA
Postgrad Med J; 1997 Jul; 73(861):409-11. PubMed ID: 9338025
[TBL] [Abstract][Full Text] [Related]
50. Enalapril: a review of human pharmacology.
Gomez HJ; Cirillo VJ; Irvin JD
Drugs; 1985; 30 Suppl 1():13-24. PubMed ID: 2994984
[TBL] [Abstract][Full Text] [Related]
51. [Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy].
Jensen BV; Nielsen SL; Jensen TS
Ugeskr Laeger; 1997 Mar; 159(13):1945-9. PubMed ID: 9123633
[TBL] [Abstract][Full Text] [Related]
52. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
Mandal AK; Markert RJ; Saklayen MG; Mankus RA; Yokokawa K
Clin Nephrol; 1994 Sep; 42(3):170-4. PubMed ID: 7994935
[TBL] [Abstract][Full Text] [Related]
53. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
MacFadyen RJ; Lees KR; Reid JL
Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
[TBL] [Abstract][Full Text] [Related]
54. Radial, carotid and aortic distensibility in congestive heart failure: effects of high-dose angiotensin-converting enzyme inhibitor or low-dose association with angiotensin type 1 receptor blockade.
Giannattasio C; Achilli F; Failla M; Capra A; Vincenzi A; Valagussa F; Mancia G
J Am Coll Cardiol; 2002 Apr; 39(8):1275-82. PubMed ID: 11955844
[TBL] [Abstract][Full Text] [Related]
55. Optimal dosing of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: a cross-sectional study in Palestine.
Sweileh WM; Sawalha AF; Rinno TM; Zyoud SH; Al-Jabi SW
Ann Saudi Med; 2009; 29(2):119-22. PubMed ID: 19318756
[TBL] [Abstract][Full Text] [Related]
56. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
Plosker GL; Sorkin EM
Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
[TBL] [Abstract][Full Text] [Related]
57. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Giri S; Mahajan SK; Sen R; Sharma A
J Assoc Physicians India; 2002 Oct; 50():1245-9. PubMed ID: 12568207
[TBL] [Abstract][Full Text] [Related]
58. [Oral enalapril in patients with symptomatic ventricular septal defects].
Vázquez-Antona CA; Simón Ruiz S; Rijlaarsdam M; Miranda Chávez I; Leiva JL; Buendía A; Attie F
Arch Inst Cardiol Mex; 1996; 66(6):496-504. PubMed ID: 9133310
[TBL] [Abstract][Full Text] [Related]
59. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
Uechi M; Imamoto S; Ishikawa Y
J Vet Med Sci; 2002 Apr; 64(4):385-7. PubMed ID: 12014588
[TBL] [Abstract][Full Text] [Related]
60. Complications during enalapril and diuretic therapy for congestive cardiac failure.
Mehta S; Vijayakumar M
Indian J Pediatr; 2009 Sep; 76(9):963-4. PubMed ID: 19904515
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
